Sucampo Pharmaceuticals, Inc. : Sucampo Appoints Silvia Taylor, MBA, as Senior Vice President, Investor Relations, Public Relations, and Corporate Communications

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that Silvia Taylor has joined the company as Senior Vice President of Investor Relations, Public Relations, and Corporate Communications, reporting to Cary J. Claiborne, Chief Financial Officer. She will lead Sucampo's investor relations, public relations, media relations and internal communications efforts with responsibility to establish the corporate brand, and to enhance Sucampo's presence among the investment audience and other stakeholder groups as well as in the different communities in which the company operates globally.

Ryuji Ueno, M.D., Ph.D., Ph.D., Chair of the Board, CEO and CSO, said, "Ms. Taylor brings extensive experience in large and mid-size public biopharmaceutical companies, and we look forward to her leadership in defining our corporate brand and overarching communications strategy among all of our corporate and product-related audiences. She will build upon the corporate awareness campaign we started earlier this month to increase awareness of Sucampo and our proprietary prostone technology. And, as a science-driven pharmaceutical company, we will benefit from her experience in launching and marketing prescription medicines as we increase patient and healthcare provider access to our flagship product AMITIZA^®, launch RESCULA^® in the United States later this year, and further develop our prostone-based pipeline to meet the needs of millions of patients around the globe."

Silvia Taylor brings 20 years of marketing and communications experience to Sucampo, including five years in public and media relations and 13 years in biopharmaceutical brand marketing at MedImmune and Pfizer Inc. She has expertise in marketing, strategy, new product launches, social media, direct-to-consumer advertising, communications, and public health, and has held leadership roles for Viagra^®, Exubera^®, motavizumab^®, Synagis^® and FluMist^® as well as other pre-launch products. Ms. Taylor joins Sucampo from MedImmune where she held positions of increasing responsibility, among them Senior Director of Marketing, RSV Franchise and Senior Director of Marketing, Global Influenza Franchise. Prior to MedImmune, Ms. Taylor worked at Pfizer from 1999 to 2007, where she worked on Viagra^® and Exubera^® and in the company's consumer marketing department on patient-directed communications. She is an expert in engaging various healthcare-related audiences using a variety of communications tools, from advertising to sales promotion to Facebook^®. Ms. Taylor's work has won numerous marketing and pharmaceutical industry awards. She graduated from the University of Virginia with a B.A. in Foreign Affairs and from Columbia Business School where she earned an MBA in Marketing and Management.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc., a global pharmaceutical company, is focused on the discovery, development, and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymatic (15-PGDH) transformation of certain fatty acids, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and currently Advisor, International Business Development, and a member of the Board of Directors. For more information, please visit www.sucampo.com.

AMITIZA is a registered trademark of Sucampo Pharmaceuticals, Inc. RESCULA is a registered trademark of R-Tech Ueno, Ltd., and has been licensed to Sucampo. Viagra and Exubera are registered trademarks of Pfizer Inc. Synagis, FluMist and motavizumab are registered trademarks of MedImmune.

Sucampo Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the US and internationally and the exposure to litigation and/or regulatory actions.

No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's Form 10-K for the year ended Dec. 31, 2011, which the Company incorporates by reference.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50326852&lang=en

Sucampo Pharmaceuticals, Inc.
Kate de Santis, +1-240-223-3834
kdesantis@sucampo.com

Partner Area